Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22012-02-010PRE
Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22012-02-011OA
Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22012-02-012PRE
New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22011-02-010OA
Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) PatientsJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22011-02-010PRE
Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22011-02-011OA
Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22011-02-010PRE
Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) PatientsJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22011-02-010PRE
IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic PropertiesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22009-02-010PRE
Recombinant human hyaluronidase facilitates dispersion of subcutaneously administered Gammagard liquid and enables administration of a full monthly bose in a single site to patients with immunodeficiency diseasesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22008-02-017OA
Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humansCLINICAL INFECTIOUS DISEASESIF7.32005-09-01560PREAI
ANTIGEN-SPECIFIC HUMORAL AND CELLULAR IMMUNE-RESPONSES DURING TREATMENT OF ADENOSINE-DEAMINASE DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY (ADA-SCID) WITH POLYETHYLENE GLYCOL-MODIFIED BOVINE ADENOSINE-DEAMINASE (PEG-ADA)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.21988-01-013PRE
ADENOSINE-DEAMINASE AND PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCIES - EVALUATION OF THERAPEUTIC INTERVENTIONS IN 8 PATIENTSJOURNAL OF CLINICAL IMMUNOLOGYIF5.71987-09-0141PREAI
INDIVIDUALIZATION OF GAMMA-GLOBULIN DOSAGE IN PATIENTS WITH HUMORAL IMMUNODEFICIENCYJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.21983-01-010PRE
T-CELLS AND SUBSETS IN A LARGE POPULATION OF PRIMARY IMMUNODEFICIENCY PATIENTSJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.21983-01-010PRE
MEMBRANE RECEPTORS AND IN-VITRO RESPONSIVENESS OF LYMPHOCYTES IN IMMUNODEFICIENCYJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.21973-02-012PRE